A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Active, not recruiting · Phase 1 · NCT02057133
Conditions: Breast Neoplasms
At a glance
- Research payments reported, 2025
- $24,813
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 198
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- LY2835219 (drug), Letrozole (drug), Anastrozole (drug), Tamoxifen (drug), Exemestane (drug), Everolimus (drug), Trastuzumab (drug), LY3023414 (drug), Fulvestrant (drug), Pertuzumab (drug), Loperamide (drug), Endocrine therapy (drug)
- Dates
- Started 2014-03-10; completion 2026-12
- Results posted
- Not yet
This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.
From ClinicalTrials.gov, last updated 2026-01-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $24,813 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Regents of the University of California $24,813
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.